» Articles » PMID: 36944195

The Effect of Hypoxia-inducible Factor Inhibition on the Phenotype of Fibroblasts in Human and Bovine Pulmonary Hypertension

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia-inducible factor (HIF) has received much attention as a potential pulmonary hypertension (PH) treatment target because inhibition of HIF reduces the severity of established PH in rodent models. However, the limitations of small-animal models of PH in predicting the therapeutic effects of pharmacologic interventions in humans PH are well known. Therefore, we sought to interrogate the role of HIFs in driving the activated phenotype of PH cells from human and bovine vessels. We first established that pulmonary arteries (PAs) from human and bovine PH lungs exhibit markedly increased expression of direct HIF target genes (, and ), as well as cytokines/chemokines (, and ), growth factors (, and ), and apoptosis-resistance genes (, and ). The expression of the genes found in the intact PAs was determined in endothelial cells, smooth muscle cells, and fibroblasts cultured from the PAs. The data showed that human and bovine pulmonary vascular fibroblasts from patients or animals with PH (termed PH-Fibs) were the cell type that exhibited the highest level and the most significant increases in the expression of cytokines/chemokines and growth factors. In addition, we found that human, but not bovine, PH-Fibs exhibit consistent misregulation of HIFα protein stability, reduced HIF1α protein hydroxylation, and increased expression of HIF target genes even in cells grown under normoxic conditions. However, whereas HIF inhibition reduced the expression of direct HIF target genes, it had no impact on other "persistently activated" genes. Thus, our study indicated that HIF inhibition alone is not sufficient to reverse the persistently activated phenotype of human and bovine PH-Fibs.

Citing Articles

Mechanisms Controlling the Behavior of Vascular Smooth Muscle Cells in Hypoxic Pulmonary Hypertension.

Bacakova L, Sedlar A, Musilkova J, Eckhardt A, Zaloudikova M, Kolar F Physiol Res. 2024; 73(S2):S569-S596.

PMID: 39589304 PMC: 11627264.


Selenium supplementation elevated SELENBP1 to inhibit fibroblast activation in pulmonary arterial hypertension.

Liang B, Lin W, Tang Y, Li T, Chen Q, Zhang W iScience. 2024; 27(10):111036.

PMID: 39435142 PMC: 11492086. DOI: 10.1016/j.isci.2024.111036.


Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α.

Wang S, Awad K, Chen L, Siddique M, Ferreyra G, Wang C Am J Physiol Lung Cell Mol Physiol. 2024; 327(4):L503-L519.

PMID: 39159362 PMC: 11482463. DOI: 10.1152/ajplung.00077.2024.


Fibroblasts in Pulmonary Hypertension: Roles and Molecular Mechanisms.

Zhang H, Li M, Hu C, Stenmark K Cells. 2024; 13(11.

PMID: 38891046 PMC: 11171669. DOI: 10.3390/cells13110914.


Expression and regulation of HIF-1a in hypoxic pulmonary hypertension: Focus on pathological mechanism and Pharmacological Treatment.

Wan J, Yi J, Wang F, Zhang C, Dai A Int J Med Sci. 2024; 21(1):45-60.

PMID: 38164358 PMC: 10750340. DOI: 10.7150/ijms.88216.


References
1.
Olschewski A, Berghausen E, Eichstaedt C, Fleischmann B, Grunig E, Grunig G . Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol. 2018; 272S:4-10. DOI: 10.1016/j.ijcard.2018.09.070. View

2.
Marsboom G, Toth P, Ryan J, Hong Z, Wu X, Fang Y . Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012; 110(11):1484-97. PMC: 3539779. DOI: 10.1161/CIRCRESAHA.111.263848. View

3.
Selimovic N, Bergh C, Andersson B, Sakiniene E, Carlsten H, Rundqvist B . Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J. 2009; 34(3):662-8. DOI: 10.1183/09031936.00174908. View

4.
Humbert M, Galie N, McLaughlin V, Rubin L, Simonneau G . An insider view on the World Symposium on Pulmonary Hypertension. Lancet Respir Med. 2019; 7(6):484-485. DOI: 10.1016/S2213-2600(19)30111-0. View

5.
Brusselmans K, Compernolle V, Tjwa M, Wiesener M, Maxwell P, Collen D . Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 2003; 111(10):1519-27. PMC: 155039. DOI: 10.1172/JCI15496. View